BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//California Life Sciences - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:California Life Sciences
X-ORIGINAL-URL:https://www.califesciences.org
X-WR-CALDESC:Events for California Life Sciences
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260701T100000
DTEND;TZID=America/New_York:20260701T110000
DTSTAMP:20260613T200413
CREATED:20260511T174029Z
LAST-MODIFIED:20260511T174029Z
UID:10001086-1782900000-1782903600@www.califesciences.org
SUMMARY:Streamlining Nonclinical Development with FDA NAMs
DESCRIPTION:FDA’s draft guidance on the validation of New Approach Methodologies (NAMs) is reshaping how nonclinical programs are designed and justified. This webinar explores how sponsors can apply NAMs to streamline development\, improve human relevance\, and support IND decision-making within a weight-of-evidence framework. \nWe will break down FDA expectations for validation\, including context of use and fit-for-purpose application\, and show how to position NAMs effectively in regulatory interactions. \nThrough real-world case examples spanning in vitro\, in silico\, and data-driven approaches\, attendees will gain practical insight into how NAMs can address data gaps\, reduce reliance on traditional models\, and strengthen nonclinical programs. \nREGISTER» \nHosted by:
URL:https://www.califesciences.org/event/streamlining-nonclinical-development-with-fda-nams/
CATEGORIES:Industry Events
ATTACH;FMTTYPE=image/png:https://www.califesciences.org/wp-content/uploads/2025/11/Virtual-Industry-Event-1.png
LOCATION:https://www.califesciences.org/event/streamlining-nonclinical-development-with-fda-nams/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260701T120000
DTEND;TZID=America/Los_Angeles:20260701T130000
DTSTAMP:20260613T200413
CREATED:20260609T175454Z
LAST-MODIFIED:20260609T175454Z
UID:10001101-1782907200-1782910800@www.califesciences.org
SUMMARY:Reading the Literature in the Age of AI
DESCRIPTION:​AI literature tools are already inside your research workflow. The question is whether you know what they’re not showing you. \n​This is 60-minute virtual session for life sciences researchers who use AI tools to find\, synthesize\, or evaluate scientific literature — and want to engage with those tools more critically. \n​We open with a real published case: a Nature Communications paper that passed peer review\, generated 22\,000 views\, and contained hundreds of errors. The correction received almost none of the attention. We’ll use it to build four specific failure mechanisms that apply to every AI literature tool you use — and a set of habits that let you catch them before they propagate into your work. \n​The session ends with a live workshop: run a real research question through two different AI tools\, compare what surfaces and what doesn’t\, and identify the failure mechanisms in action. \n​No technical background needed. Just bring a research question you’d actually use. \n​Who this is for: Post-docs\, research scientists\, PIs\, and anyone in life sciences who uses AI tools for literature search\, synthesis\, or research evaluation. \nREGISTER» \nHosted by:
URL:https://www.califesciences.org/event/reading-the-literature-in-the-age-of-ai/
CATEGORIES:Industry Events,Industry Supported,Professional Development
ATTACH;FMTTYPE=image/png:https://www.califesciences.org/wp-content/uploads/2025/11/Virtual-Industry-Event-1.png
LOCATION:https://www.califesciences.org/event/reading-the-literature-in-the-age-of-ai/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260722T090000
DTEND;TZID=America/Los_Angeles:20260722T100000
DTSTAMP:20260613T200413
CREATED:20260611T234114Z
LAST-MODIFIED:20260611T234114Z
UID:10001103-1784710800-1784714400@www.califesciences.org
SUMMARY:A Hybrid Fragmentation Strategy for Modified Oligos
DESCRIPTION:About this webinar\nMass-spectrometric sequencing of therapeutic oligonucleotides is constrained by the choice of fragmentation method. Electron-transfer dissociation (ETD) struggles to fully fragment modified backbones — particularly locked nucleic acids (LNA) — and higher-energy collisional dissociation (HCD) produces dense spectra that are slow to interpret and prone to coverage gaps. For antisense oligos that combine LNA modifications with phosphorothioate (PS) backbones\, neither approach on its own delivers reliable end-to-end coverage. \nThis webinar presents a hybrid fragmentation approach that combines ETD and HCD in a single Orbitrap scan (EThcD)\, applied across a panel of 16-mer modified oligonucleotides — LNA-containing antisense oligos\, full PS and PO backbones\, and PS/PO mixtures. The method gives full sequence coverage from w-ions alone\, with cleaner spectra than HCD and a controlled\, a/w- and d/z-dominant fragment pattern suitable for automated assignment in Byos. Kevin will also walk through the Byos processing recipe used to interpret the data and the optimal EThcD energy identified for the 16-mer panel. \nKey Takeaways\n\nA single Orbitrap scan that covers modified oligos end-to-end. EThcD on highly-charged anionic precursors yields full w-ion coverage on LNA-containing antisense oligonucleotides and PS-backbone samples where ETD and HCD alone leave gaps.\nA counter-intuitive PS-versus-PO finding. Phosphorothioate backbones fragment more efficiently under EThcD than phosphodiester backbones — with direct implications for impurity screening in PS therapeutics.\nA practical EThcD processing recipe in Byos. Recommended energy settings\, fragment-type configuration\, and a strict-then-lenient pass strategy for confident sequence coverage and impurity detection.\n\nSpeaker\nKevin Hes — PhD candidate\, Division of BioAnalytical Chemistry & MS-LaserLab\, Vrije Universiteit Amsterdam. PhD jointly sponsored by AstraZeneca\, GSK\, and Novartis\, with funding from the Dutch Research Council (NWO); co-supervised by Anouk Rijs and Govert Somsen. Part of the InnovATOR consortium InnovATOR consortium. \nREGISTER» \nHosted by:
URL:https://www.califesciences.org/event/oligo-hybrid-fragmentation/
CATEGORIES:Industry Events,Industry Supported
ATTACH;FMTTYPE=image/png:https://www.califesciences.org/wp-content/uploads/2025/11/Virtual-Industry-Event-1.png
LOCATION:https://www.califesciences.org/event/oligo-hybrid-fragmentation/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260722T140000
DTEND;TZID=America/Los_Angeles:20260722T150000
DTSTAMP:20260613T200413
CREATED:20260610T174519Z
LAST-MODIFIED:20260610T174519Z
UID:10001102-1784728800-1784732400@www.califesciences.org
SUMMARY:From Clinical to Commercial: Talent Strategies for Biopharma Growth
DESCRIPTION:Early indications in 2026 are pointing towards a slight recovery in the biopharma job market. Join industry hiring experts for a data-informed discussion on where the life sciences job market stands today\, what trends we are witnessing in hiring and how hiring managers and HR and talent acquisition professionals can navigate shifts towards commercial readiness and/or building out commercial teams. \nThis webinar will provide a clear-eyed assessment of current hiring conditions across biopharma\, exploring how the economic climate is impacting workforce development and how hiring practices are evolving as organizations prepare to take products to market. \nREGISTER» \nHosted by:
URL:https://www.califesciences.org/event/from-clinical-to-commercial-talent-strategies-for-biopharma-growth/
CATEGORIES:Industry Events,Industry Supported
ATTACH;FMTTYPE=image/png:https://www.califesciences.org/wp-content/uploads/2025/11/Virtual-Industry-Event-1.png
LOCATION:https://www.califesciences.org/event/from-clinical-to-commercial-talent-strategies-for-biopharma-growth/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260729T090000
DTEND;TZID=America/Los_Angeles:20260729T100000
DTSTAMP:20260613T200413
CREATED:20260611T234345Z
LAST-MODIFIED:20260611T234345Z
UID:10001104-1785315600-1785319200@www.califesciences.org
SUMMARY:Footprints Without Footwork: Automated Benchtop HRPF for Binding Partners and Interfaces
DESCRIPTION:About this Webinar\nEvery protein leaves a footprint — the surface-exposed side chains that are accessible when it folds\, when it binds\, when it changes shape. Hydroxyl radical protein footprinting (HRPF) reads those footprints by oxidising the exposed residues and leaving the buried ones alone — a structural mass spectrometry technique that runs on standard laboratory equipment plus a benchtop Fenton reaction. Done by hand it is labor-intensive: multiple radical concentrations\, replicate reactions\, and dose-response curves that are sensitive to pipetting variability. Manual HRPF also limits the technique in scope — applying it across the dozens of pulldowns needed to characterise a complex becomes impractical. \nIn this webinar we show how moving the workflow onto the Opentrons Flex liquid handler tightens reproducibility and lifts throughput\, and how applying that automated workflow to affinity-purified protein complexes lets you identify binding partners and map their interaction interfaces in the same experiment. \nWhat you’ll learn in this webinar:\n\nHRPF can be performed using standard laboratory equipment to probe surface-accessible amino acids on proteins and protein complexes\nAutomating HRPF reactions on the Opentrons Flex reduces variability and increases throughput\nPerforming HRPF reactions on affinity-purified protein complexes can provide insights into binding partners and interfaces simultaneously\n\nOur Speaker:\nTyler Cropley is a Research Scientist in the Proteomics Laboratory at NYU Langone Health under the supervision of Dr. Beatrix Ueberheide. His work focuses on using mass spectrometry-based methods to study higher-order protein structure. He earned his PhD from Florida State University under the supervision of Dr. Christian Bleiholder. \nREGISTER» \nHosted by:
URL:https://www.califesciences.org/event/nyu-footprint-2026/
CATEGORIES:Industry Events,Industry Supported
ATTACH;FMTTYPE=image/png:https://www.califesciences.org/wp-content/uploads/2025/11/Virtual-Industry-Event-1.png
LOCATION:https://www.califesciences.org/event/nyu-footprint-2026/
END:VEVENT
END:VCALENDAR